Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Bausch Health Companies
(NYSE:BHC)
Intraday
$8.53
0.08
[0.95%]
After-Hours
$8.53
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$8.53
0.08
[0.95%]
At close: Apr 23
$8.53
0
[0.00%]
After Hours: 4:02PM EDT
Get Report
Watch
Q1 2024 Earnings in 9 days from now on Thu May 2nd, before the market open
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Bausch Health Companies Stock (NYSE:BHC)
Bausch Health Companies Stock (NYSE: BHC)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, April 23, 2024
RBC Capital Maintains Sector Perform on Bausch Health Companies, Lowers Price Target to $11
Benzinga Newsdesk
-
7 hours ago
Friday, April 12, 2024
RBC Capital Reiterates Sector Perform on Bausch Health Companies, Maintains $12 Price Target
Benzinga Newsdesk
-
Apr 12, 2024, 10:15AM
Thursday, April 11, 2024
U.S. Appeals Court Says Bausch Can Block Alvogen From Copying Xifaxan Diarrhea Drug Until 2029
Benzinga Newsdesk
-
Apr 11, 2024, 11:50AM
Bausch Health Companies Appeals Court Ruling Out On Bausch Health/Salix Vs Norwich On Xifaxan
Benzinga Newsdesk
-
Apr 11, 2024, 10:59AM
Acne Vulgaris Treatment PrARAZLO Now Available To Patients Through British Columbia PharmaCare Public Drug Plan
Benzinga Newsdesk
-
Apr 11, 2024, 8:04AM
Friday, April 05, 2024
Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
Benzinga Newsdesk
-
Apr 5, 2024, 6:27PM
RBC Capital Maintains Sector Perform on Bausch Health Companies, Raises Price Target to $12
Benzinga Newsdesk
-
Apr 5, 2024, 7:21AM
Wednesday, April 03, 2024
Bausch Health, Canada Announces First Public Drug Plan Listings for (Pr)UCERIS(R) Aerosol Foam To Help Address Unmet Need For Treatment Of Mild To Moderate Distal Ulcerative Colitis In Adults
Benzinga Newsdesk
-
Apr 3, 2024, 8:08AM
Wednesday, March 06, 2024
Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study Of RELISTOR In Patients With Resectable Head And Neck Squamous Cell Carcinoma
Benzinga Newsdesk
-
Mar 6, 2024, 8:05AM
Friday, February 23, 2024
RBC Capital Maintains Sector Perform Rating for Bausch Health Companies: Here's What You Need To Know
Benzinga Insights
-
Feb 23, 2024, 12:00PM
RBC Capital Maintains Sector Perform on Bausch Health Companies, Raises Price Target to $9
Benzinga Newsdesk
-
Feb 23, 2024, 10:29AM
Thursday, February 22, 2024
Looking At Bausch Health Companies's Recent Unusual Options Activity
Benzinga Insights
-
Feb 22, 2024, 12:15PM
Bausch Health Companies shares are trading higher after the company reported better-than-expected Q4 revenue results and issued FY24 revenue guidance above estimates.
Benzinga Newsdesk
-
Feb 22, 2024, 11:57AM
Bausch Health Companies Forecasts 2024 Revenues Of $9.3B-$9.55B Versus Consensus Of $8.97B, with Adjusted EBITDA Of $3.20B-$3.35B
Benzinga Newsdesk
-
Feb 22, 2024, 7:15AM
Bausch Health Companies Q4 Sales $2.41B Beat $2.30B Estimate, Adjusted Net Income Of $406M
Benzinga Newsdesk
-
Feb 22, 2024, 7:12AM
Earnings Scheduled For February 22, 2024
Benzinga Insights
-
Feb 22, 2024, 5:27AM
Wednesday, February 21, 2024
Preview: Bausch Health Companies's Earnings
Benzinga Insights
-
Feb 21, 2024, 10:01AM
Thursday, February 08, 2024
A 'Toxic Byproduct of an Imperfect Higher Education System' — Famous Short Seller Known as 'The Assassin' Strikes Her Newest Target
Caleb Naysmith
-
Feb 8, 2024, 8:59AM
Tuesday, January 30, 2024
CABTREO(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide) Topical Gel for the Treatment of Acne Vulgaris Now Available in the US
Benzinga Newsdesk
-
Jan 30, 2024, 8:06AM
Thursday, January 18, 2024
Solta Medical's Thermage FLX And TR-4 Return Pad Receive Registration Certifications In China
Benzinga Newsdesk
-
Jan 18, 2024, 8:06AM
Thursday, December 21, 2023
Spotlight on Bausch Health Companies: Analyzing the Surge in Options Activity
Benzinga Insights
-
Dec 21, 2023, 3:01PM
Bausch Health Announces Topline Results From Global Phase 2 Study Evaluating Amiselimod (An S1P Sntagonist) to Treat Ulcerative Colitis
Benzinga Newsdesk
-
Dec 21, 2023, 7:04AM
Monday, December 18, 2023
Bausch Health, Canada, Part Of Bausch Health Companies Announced That DUOBRII Is Now Available To Patients Enrolled In Quebec's Public Drug Plan Operated By The Régie De L'assurance Maladie Du Québec
Benzinga Newsdesk
-
Dec 18, 2023, 8:06AM
Friday, November 10, 2023
The Absence Of An Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result In Increased OHE-Related Length Of Stay And Hospitalization-Related Costs Due To OHE Rate Underestimation, According To New Analysis
Benzinga Newsdesk
-
Nov 10, 2023, 8:05AM
Thursday, November 02, 2023
Green Wave Boosts Stocks, Bonds As Traders Embrace Fed's Stance, Await Apple Earnings: What's Driving Markets Thursday?
Shanthi Rexaline
-
Nov 2, 2023, 1:58PM
Bausch Health Companies Reports Q3 Adjusted Net Income Of $377M Versus $277M A Year Ago
Benzinga Newsdesk
-
Nov 2, 2023, 7:18AM
Bausch Health Companies Q3 Sales $2.24B Beat $2.15B Estimate
Benzinga Newsdesk
-
Nov 2, 2023, 7:17AM
Earnings Scheduled For November 2, 2023
Benzinga Insights
-
Nov 2, 2023, 4:56AM
Wednesday, November 01, 2023
U.S. District Court Dismisses Norwich's Lawsuit Against The FDA
Benzinga Newsdesk
-
Nov 1, 2023, 12:24PM
Monday, October 30, 2023
Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week
Shanthi Rexaline
-
Oct 30, 2023, 3:40AM
Saturday, October 28, 2023
Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More
Nabaparna Bhattacharya
-
Oct 28, 2023, 12:49PM
Tuesday, October 10, 2023
Salix Pharmaceuticals Releases Liver Health Annual Trends Report Identifying Increase In Chronic Liver Disease And Cirrhosis-Related Deaths Marking These As Ninth Leading Cause Of Death In U.S.
Benzinga Newsdesk
-
Oct 10, 2023, 8:10AM
Wednesday, September 20, 2023
Benzinga's Top Ratings Upgrades, Downgrades For September 20, 2023
Benzinga Insights
-
Sep 20, 2023, 11:00AM
Steelcase, Western Digital, Bausch Health And Other Big Stocks Moving Higher On Wednesday
Lisa Levin
-
Sep 20, 2023, 10:53AM
Bausch Health Companies shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $9 to $16.
Benzinga Newsdesk
-
Sep 20, 2023, 8:40AM
Jefferies Upgrades Bausch Health Companies to Buy, Raises Price Target to $16
Benzinga Newsdesk
-
Sep 20, 2023, 5:11AM
Tuesday, September 19, 2023
Bausch Health Companies shares are trading lower. The company announced that CFO Tom Vadaketh has resigned from his role.
Benzinga Newsdesk
-
Sep 19, 2023, 2:04PM
Monday, September 18, 2023
Bausch Health Companies Says CFO Tom Vadaketh Has Resigned From His Role To Pursue Another Opportunity,
Benzinga Newsdesk
-
Sep 18, 2023, 5:36PM
Thursday, September 07, 2023
Bausch Health's Bausch + Lomb Discloses Historical And Pro Forma Financial Information For XIIDRA Acquisition
Benzinga Newsdesk
-
Sep 7, 2023, 1:10AM
Thursday, August 03, 2023
Stocks Mitigate Losses Ahead Of Apple, Amazon Earnings; Treasury Yields Rocket On Debt Frenzy: Thursday's Market Drivers
Shanthi Rexaline
-
Aug 3, 2023, 1:53PM
Earnings Scheduled For August 3, 2023
Benzinga Insights
-
Aug 3, 2023, 6:59AM
Monday, July 17, 2023
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin
-
Jul 17, 2023, 1:14PM
Monday, July 10, 2023
Breather For Carl Icahn: Revised Loan Agreements and Recovery Strategy Post Short-Seller Attack
Vandana Singh
-
Jul 10, 2023, 8:15AM
Friday, June 30, 2023
Bausch + Lomb Poised To Boost Presence In Growing Market With Potential $1.75B Drug Acquisition Deal From Novartis
Vandana Singh
-
Jun 30, 2023, 8:40AM
Bausch + Lomb to Pay $1.75B for Eye Drug From Novartis
Charles Gross
-
Jun 30, 2023, 7:01AM
Friday, June 16, 2023
Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2023
Benzinga Insights
-
Jun 16, 2023, 11:01AM
TD Cowen Downgrades Bausch Health Companies to Market Perform
Benzinga Newsdesk
-
Jun 16, 2023, 7:20AM
Tuesday, June 06, 2023
Bausch Health Companies Unusual Options Activity
Benzinga Insights
-
Jun 6, 2023, 3:31PM
Why THOR Industries Shares Are Trading Higher By 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
-
Jun 6, 2023, 1:04PM
Coinbase, Blue Bird, Tingo Group And Other Big Stocks Moving Lower On Tuesday
Lisa Levin
-
Jun 6, 2023, 11:35AM
Show more